Jane Street Group LLC Purchases New Shares in Anixa Biosciences, Inc. (NASDAQ:ANIX)

Jane Street Group LLC acquired a new position in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 28,846 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned 0.09% of Anixa Biosciences at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Prosperity Wealth Management Inc. purchased a new stake in shares of Anixa Biosciences in the 4th quarter valued at approximately $54,000. LPL Financial LLC lifted its holdings in shares of Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after purchasing an additional 11,633 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after buying an additional 3,900 shares during the period. 29.13% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Amit Kumar purchased 10,000 shares of the stock in a transaction on Wednesday, June 4th. The shares were purchased at an average cost of $2.85 per share, with a total value of $28,500.00. Following the acquisition, the chief executive officer now directly owns 569,925 shares in the company, valued at $1,624,286.25. The trade was a 1.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 25.30% of the stock is owned by corporate insiders.

Anixa Biosciences Price Performance

Shares of ANIX opened at $2.76 on Monday. The company has a market capitalization of $88.90 million, a P/E ratio of -7.08 and a beta of 0.34. The business’s 50 day simple moving average is $2.66 and its 200-day simple moving average is $2.79. Anixa Biosciences, Inc. has a one year low of $2.07 and a one year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. On average, sell-side analysts anticipate that Anixa Biosciences, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ANIX has been the subject of several research analyst reports. Maxim Group began coverage on Anixa Biosciences in a research note on Friday, March 21st. They issued a “buy” rating and a $10.00 price objective for the company. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Thursday, May 29th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, March 25th. Finally, Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Anixa Biosciences currently has a consensus rating of “Buy” and an average target price of $9.00.

Anixa Biosciences Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.